Psychotic depression - Beyond the antidepressant/antipsychotic combination

Current Psychiatry Reports

Volumn 14, Issue 6, 2012, Pages 619-623

  Nelson, Erik B ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

Antidepressant monotherapy; Antidepressant antipsychotic combination; Antipsychotic monotherapy; Delusional depression; Depressive subtypes; Fludrocortisone; HPA axis dysregulation; Major depression with psychotic features; Mineralocorticoid receptor; MR; Nonpsychotic depression; Psychiatry; Psychotic depression; Psychotic mood disorders; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; HYDROCORTISONE; MIFEPRISTONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DEPRESSIVE PSYCHOSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FAMILY HISTORY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MONOTHERAPY; PHENOMENOLOGY; TREATMENT RESPONSE;

AFFECTIVE DISORDERS, PSYCHOTIC; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FLUDROCORTISONE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS;

EID: 84870791793     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0315-6     Document Type: Article

References (45)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Association; 1995.
2. Johnson J, Horwath E, Weissman M. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry. 1991;48:1075-81.
3. Roose S, Glassman A. Delusional depression. In: Georgotas A, Cancro R, editors. Depression and mania. New York: Esevier Science Publishing Co., Inc.; 1988. p. 76-85.
4. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry. 1981;138:328-33. (Pubitemid 11155881)
5. Frances A, Brown RP, Kocsis JH, Mann JJ. Psychotic depression: a separate entity? Am J Psychiatry. 1981;138:831-3. (Pubitemid 11123126)
6. Schatzberg A, Rothschild A. Psychotic (delusional) depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733-45.
7. Coryell W, Tsuang M. Primary unipolar depression and the prognostic importance of delusions. Arch Gen Psychiatry. 1982;39:1181-4. (Pubitemid 12034172)
8. Coryell W, Endicott J, Keller M. The importance of psychotic features to major depression: course and outcome during a 2-year follow-up. Acta Psychiatr Scand. 1987;75:78-85. 1Using Smart Source Parsing Jan. (Pubitemid 17019557)
9. Robinson DG, Spiker DG. Delusional depression: a one year follow-up. J Affect Disord. 1985;9:79-83. (Pubitemid 15068951)
10. Lykouras L, Christodoulou GN, Malliaras D, Stefanis C. The prognostic importance of delusions in depression: a 6-year prospective follow-up study. J Affective Disord. 1994;32:233-8.
11. Tohen M, Khalsa H-MK, Salvatore P, Vieta E, Ravichandran C, Baldessarini RJ. Two-year outcomes in first-episode psychotic depression the McLean-Harvard First-Episode Project. J Affect Disord. 2012;136(1-2):1-8.
12. Perlis RH, Uher R, Ostacher M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011;68 (4):351-60.
13. Rothschild A. Delusional depression: a review of the literature and current perspectives. McLean Hosp J. 1985;10:68-84.
14. Parker G, Hadzi-Pavlovic D, Hickie I, Boyce P, et al. Distinguishing psychotic and non-psychotic melancholia. J Affect Disord. 1991;22:135-48. 3Using Smart Source Parsing Jul.
15. Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. Ann N Y Acad Sci. 1988;537:462-71. Using Smart Source Parsing Oct. (Pubitemid 19029566)
16. Anton RF. Urinary free cortisol in psychotic depression. Biol Psychiatry. 1987;22:24-34. 1Using Smart Source Parsing Jan. (Pubitemid 17229949)
17. Rothschild A, Schatzberg A, Langlais P, et al. Psychotic and nonpsychotic depression: comparison of plasma catecholamines and cortisol measures. Psych Res. 1987;20:143-53. (Pubitemid 17033635)
18. Lembke A, Gomez R, Tenakoon L, et al. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitaryadrenal activity in humans with psychotic major depression. Psychoneuroendocrinology. 2012.
19. Garrett A, Kelly R, Gomez R, Keller J, Schatzberg AF, Reiss AL. Aberrant brain activation during a working memory task in psychotic major depression. Am J Psychiatry. 2011;168(2):173-82.
20. Simpson G, Lee J, Cuculic Z, Keller R. Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Arch Gen Psych. 1976;33:1093-102.
21. Glassman A, Kantor S, Shostak M. Depression, delusions and drug response. Am J Psychiatry. 1975;136:559-62.
22. Lykouras EP, Malliaras D, Christodoulou GN, Papakostas Y, et al. Delusional depression: phenomenology and response to treatment: a prospective study. Acta Psychiatr Scand. 1986;73:324-9. (Pubitemid 16116257)
23. Simpson GM, El Sheshai A, Rady A, Kingsbury SJ, Fayek M. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. J Clin Psychiatry. 2003;64(8):959-65. (Pubitemid 37022765)
24. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244-53. (Pubitemid 33131305)
25. Pande AC, Grunhaus LJ, Haskett RF, Greden JF. Electroconvulsive therapy in delusional and non-delusional depressive disorder. J Affect Disord. 1990;19(3):215-9. (Pubitemid 20209138)
26. Janicak PG, Easton MS, Comaty JE, Dowd S, Davis JM. Efficacy of ECT in psychotic and nonpsychotic depression. Convuls Ther. 1989;5(4):314-20. (Pubitemid 20045620)
27. Birkenhäger TK, Pluijms EM, Lucius SAP. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord. 2003;74(2):191-5. (Pubitemid 36428701)
28. Solan WJ, Khan A, Avery DH, Cohen S. Psychotic and nonpsychotic depression: comparison of response to ECT. J Clin Psychiatry. 1988;49(3):97-9. (Pubitemid 18091341)
29. Rich CL, Spiker DG, Jewell SW, Neil JF, Phillipson M. ECT response in psychotic versus nonpsychotic unipolar depressives. J Clin Psychiatry. 1986;47(3):123-5. (Pubitemid 16166352)
30. Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66(8):838-47.
31. Rothschild AJ, Phillips KA. Selective serotonin reuptake inhibitors and delusional depression. Am J Psychiatry. 1999;156(6):977-8. (Pubitemid 29260373)
32. Spiker DG, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985;142:430-6. (Pubitemid 15108205)
33. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord. 1992;24:17-24. 1Using Smart Source Parsing Jan.
34. Clower C. Recurrent psychotic unipolar depression. J Clin Psychiatry. 1983;44:216-8.
35. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73 (4):486-96.
36. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001;21(5):516-21. (Pubitemid 32937434)
37. Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52(5):386-92. (Pubitemid 35266729)
38. DeBattista C, Belanoff J, Glass S, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry. 2006;60(12):1343-9. (Pubitemid 44838535)
39. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31(3):628-36. (Pubitemid 43276978)
40. Nihalani ND, Schwartz TL. Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Curr Opin Investig Drugs. 2007;8(7):563-9. (Pubitemid 47016324)
41. Simpson GM, El Sheshai A, Loza N, et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry. 2005;66(5):598-602. (Pubitemid 40733702)
42. Blasey CM, Debattista C, Roe R, Block T, Belanoff JK. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp Clin Trials. 2009;30(4):284-8.
43. Blumberger DM, Mulsant BH, Emeremni C, et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatr Res. 2011;45(7):896-901.
44. Weissman J, Flint A, Meyers B, et al. Factors associated with noncompletion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research. 2012.
45. Nelson EB, McElroy SL. Psychotic depression: a guide to drug choice. CNS Drugs. 1997;8:457-73. (Pubitemid 28049888)